Tag: licensing
-
Patents, Start-Ups Increase in 2013 at U.S. University Labs
10 September 2014. The numbers of patents filed, licensing income, and start-ups generated by research at U.S. universities last year all increased, according to an annual survey conducted by the Association of University Technology Managers (AUTM), the organization of university staff responsible for research commercialization. The survey covers 202 responding institutions of 299 contacted, or…
-
U.S. Patent Awarded for Freeze-Dried Vaccine Formulation
9 September 2014. The technology making possible production and shipping of vaccines in a stable freeze-dried state received U.S. patent protection. Patent no. 8,808,710 was awarded last month by the U.S. Patent and Trademark Office to four inventors and assigned to University of Colorado. Soligenix Inc. in Princeton, New Jersey licensed the technology from University…
-
Analysis Uncovers Biotech Commercialization Bottlenecks
21 August 2014. The path from scientific discovery in an academic lab to the marketplace is rarely a straightforward process, with researchers and entrepreneurs often facing detours and delays keeping new biomedical technologies in limbo for years at a time. Those are the conclusions of faculty at Georgia Institute of Technology’s business school that studied…
-
Licensing Deal Combines Genomics, Placenta Stem Cells
11 August 2014. A new licensing agreement will make available research by Celgene Cellular Therapeutics on stem cells from the placenta to Human Longevity Inc., a company specializing in genomics for age-related disorders. Financial aspects of the agreement were not disclosed, but as part of the deal, Celgene is expected to make an equity investment…
-
Challenge Seeks Biomarkers for Neuropathic Pain
1 August 2014. A new challenge on InnoCentive is seeking biomarkers that help predict the effectiveness of pain-killing therapies for patients with neuropathic pain. The challenge requires a detailed written proposal due on 27 September 2014, with a payout of $25,000. Free registration is required to see the challenge details. InnoCentive in Waltham, Massachusetts conducts…
-
Cancer Screening Blood Test Proposed, New Company Formed
28 July 2014. A team from University of Bradford in the U.K. developed a simple blood test, which in early tests suggests it could screen patients for common types of cancer. The researchers led by medical sciences professor Diana Anderson published their findings last Friday in FASEB Journal, published by Federation of American Societies for…
-
Organ Chip Start-Up Gains $12 Million in Early Funds
28 July 2014. Emulate Inc., a new company spun-off from a Harvard University bioengineering lab, raised $12 million in its first venture round to finance development of chip-like devices that mimic the functions of human organs. The funding round was led by NanoDimension, a venture capital company specializing in nanotechnologies, with Cedars-Sinai Medical Center and…
-
Trial Shows Drug Not Extending Breast Cancer Survival Time
25 July 2014. A late-stage clinical trial of the cancer drug sorafenib shows the drug, combined with the chemotherapy drug capecitabine, does not extend the amount of progression-free survival time of advanced breast cancer patients, compared to capecitabine alone. Sorafenib, marketed under the brand name Nexavar, is made by Onyx Pharmaceuticals in South San Francisco,…
-
Novartis Licensing Smart Lens Technology from Google
15 July 2014. The Alcon division of pharmaceutical company Novartis is licensing the rights to Google’s so-called smart lens technology for medical applications involving the eyes. Financial terms of the licensing agreement between Alcon that develops vision care products for Novartis and Google[x], part of the company’s research labs, were not disclosed. Google[x] announced in…
-
Baxter Acquires Sickle-Cell Prevention Drug Developer
10 July 2014. Baxter International in Deerfield, Illinois is acquiring AesRx LLC, a biopharmaceutical company in Newton, Massachusetts developing drugs for sickle-cell and other rare diseases. Baxter is making an initial payment to AesRx, which will be eligible for future payments tied to development and commercial milestones, but dollar amounts were not disclosed. Sickle cell…